27558 Obeticholic acid (OCALIVA ®) protects against 2,8-dihydroxyadenine nephropathy in mice
ABSTRACT IMPACT: This work may lead to new treatments for crystalline nephropathies. OBJECTIVES/GOALS: This study investigated obeticholic acid (OCALIVA ®) as a potential treatment for 2,8-dihydroxyadenine (2,8-DHA) nephropathy using a mouse model. The treatment was investigated in both sexes at two...
Main Authors: | Bryce Jones, Carlos Benitez, Idalia Cruz, Komuraiah Myakala, Xiaoxin Wang, Andrew Libby, Emma Rowland, Ryan Kurtz, Avi Rosenberg, Moshe Levi |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-03-01
|
Series: | Journal of Clinical and Translational Science |
Online Access: | https://www.cambridge.org/core/product/identifier/S2059866121004283/type/journal_article |
Similar Items
-
Inflammation plays a critical role in 2,8-dihydroxyadenine nephropathy
by: Bouderlique, Elise, et al.
Published: (2021-08-01) -
4528 Sirtuin 3 activation as a potential renoprotective therapy in a mouse model of Alport syndrome
by: Bryce Jones, et al.
Published: (2020-06-01) -
Sodium benzoate attenuates 2,8-dihydroxyadenine nephropathy by inhibiting monocyte/macrophage TNF-α expression
by: Yoichi Oshima, et al.
Published: (2023-02-01) -
2,8-Dihydroxyadenine nephrolithiasis with chronic kidney disease in children: A case report and review of literature
by: Rizky Ramdhani, et al.
Published: (2023-11-01) -
Kidney Biopsy Techniques to Differentiate Calcium Oxalate and Dihydroxyadenine Tubular Crystals
by: Dalia Ibrahim, MD, et al.
Published: (2022-09-01)